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We have characterized the expression of transform-
ing growth factor a (TGFa) and its receptor, the
epidermal growth factor receptor (EGF-R), in normal
and malignantly transformed human mammary epi-
thelial cells. Human mammary epithelial cells were
derived from a reduction mammoplasty (184), im-
mortalized by benzo-a-pyrene (184A1N4), and fur-
ther transformed by the oncogenes simian virus 40
T (SV40 T), v-Ha-ras, and v-mos alone or in combi-
nation using retroviral vectors. 184 and 184A1N4
cells require EGF for anchorage-dependent clonal
growth. In mass culture, they secrete TGFa at high
concentrations and exhibit an attenuated require-
ment for exogenous EGF/TGFa. SV40 T transformed
cells have 4-fold increased EGF-R, have acquired
the ability to clone in soft agar with EGF/TGFa
supplementation, but are not tumorigenic. Cells
transformed by v-mos or v-Ha-ras are weakly tu-
morigenic and capable of both anchorage depend-
ent and independent growth in the absence of EGF/
TGFa. Cells transformed by both SV40 T and v-Ha-
ras are highly tumorigenic, are refractory to EGF/
TGFa, and clone with high efficiency in soft agar.
The expression of v-Ha-ras is associated with a loss
of the high (but not low) affinity binding component
of the EGF-R. Malignant transformation and loss of
TGFa/EGF responsiveness did not correlate with an
increase in TGFa production. Thus, TGFa production
does not appear to be a tumor specific marker for
human mammary epithelial cells. Differential growth
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responses to EGF/TGFa, rather than enhanced pro-
duction of TGFa, may determine the transition from
normal to malignant human breast epithelium. (Mo-
lecular Endocrinology 3: 203-214, 1989)
INTRODUCTION
Transforming growth factor alpha (TGFa) is a mitogenic
polypeptide produced by a variety of retrovirally, chem-
ically, or oncogene-transformed human and rodent cell
lines (1). TGFa is also present in human mammary
tumor tissues and cell lines (2-4), and has recently been
demonstrated in normal human keratinocytes (5). TGFa
is operationally defined by its ability to reversibly induce
the transformed phenotype as measured by anchorage-
independent cloning of normal rat kidney (NRK) cells
(6). Structurally and functionally related to epidermal
growth factor (EGF), TGFa competes with EGF for
binding to the same receptor (7). Transformed cells in
vitro generally synthesize and secrete TGFa, demon-
strate a partial or complete relaxation of their growth
factor requirements, and exhibit a down-regulation of
their cell surface EGF receptors (EGF-R), as defined by
reduced ligand binding capacity (1, 8). It was proposed
in the autocrine hypothesis (9), that the TGFa produced
by transformed cells could act on the cells' own EGF
receptors to promote unrestrained cellular proliferation.
We have previously demonstrated expression of
TGFa mRNA in several human breast cancer cell lines
and in approximately 70% of primary infiltrating ductal
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breast carcinomas, as well as evidence for a possible
autocrine pathway for TGFa in hormone-dependent
human breast cancer cells in vitro (10). Similarly, a role
for EGF/TGFa in supporting the limited in vivo growth
of xenografts of the human estrogen-responsive breast
cancer cell line MCF-7 has also been described (11).
Modulation of EGF-R levels may also have an important
role in human breast neoplasia. In two recent studies,
increased numbers of EGF-R in human breast cancer
cell lines and in breast tumor biopsies have been cor-
related with increased rates of proliferation (12) and
with clinically more aggressive mammary malignancies
(13).
Protooncogene expression has also been studied in
breast cancer (14-18). Overexpression of p21 ras pro-
tein has been found in human breast cancer biopsies
(14), and increased production of TGFa and a loss of
responsiveness to exogenous EGF or TGFa has been
reported after transfection of MCF-7 human breast
cancer cells with v-Ha-ras oncogene (15) or after trans-
formation of normal mouse mammary epithelial cells
with a point-mutated c-Ha-ras protooncogene (16). In
addition, point mutations of the c-Ha-ras and c-Ki-ras
genes have been observed in two TGFa refractory and
hormone-independent breast cancer cell lines (Hs578T
and MDA MB-231, respectively) (17,18).
The present study was undertaken to examine the
level of expression of TGFa and the EGF-R in normal
human mammary epithelial cells (HMEC) and in HMEC
after immortalization and after oncogene transforma-
tion. Long-term growth of nontransformed HMEC has
been achieved with reduction mammoplasties of young,
nonpregnant, nonlactating women (19). These cell
strains are characterized by complex media require-
ments, contact inhibition, lack of anchorage-independ-
ent growth, lack of tumorigenicity, and senescence after
12-22 passages in culture. An immortalized clonal cell
line, 184A1N4, was established after benzo-a-pyrene
treatment of the normal HMEC 184 cells (20). Malig-
nantly transformed sublines of the 184A1N4 cells were
made by introducing the oncogenes v-mos, v-Ha-ras,
Table 1. Characteristics of the HMEC
Cell Cloning Efficiency(in soft agar) Tumorigenicity
Doubling Times
(h)
184
184A1N4
184A1N4-T
184A1N4-M
184A1N4-H
184A1N4-MH
184A1N4-TH
<0.1%
<0.1%
<0.1%
0.6%
0.6%
2.3%
27.5%
0
0
0
±
+
+
++
20 ± 4
32 ± 6
32 ± 5
48 ±20
21 ± 5
30 ± 5
30 ± 3
Cloning efficiencies in soft agar was tested with 2 x 1 0 " cells
plated in their respective regular growth medium with 0.36%
Bacto agar in 35-mm dishes. Colonies were counted after 9-
11 days incubation, scoring colonies with greater than or equal
to 60 fim diameter as positive. Tumorigenicity was tested as
described (21) in nude athymic mice (Balb/c Nu/Nu) using 4 x
106 cells in Dulbecco's PBS after sc injections. Twenty days
post inoculation, animals were killed and examined for tumors.
and simian virus 40 T (SV40 T), through retroviral vector
infection (21). The cell lines thus established displayed
marked variations in expression of the transformed
phenotype, ranging from lack of anchorage-independ-
ent growth and tumorigenicity, to highly anchorage-
independent and fully tumorigenic (Table 1). None of
the 184-derived cells were found to express the estro-
gen receptor, as determined by binding assays or im-
munocytochemistry (unpublished data). Since transfor-
mation has been reported to lead to overproduction of
growth factors such as TGFa, receptor desensitization
and receptor down-regulation (1), the aims of this study
were to establish whether nontransformed HMEC ex-
press TGFa as well as the EGF-R, and to elucidate the
influence of oncogenic transformation in human mam-
mary epithelial cells on the TGFa/EGF-receptor system.
We sought to determine whether these phenotypic
variations among nonneoplastic and transformed
HMEC could be correlated with alterations in the re-
sponse to exogenous TGFa, production of endogenous
TGFa, or EGF-R expression.
RESULTS
Growth Responses of the HMEC to EGF/TGFa
184 and 184A1N4 were found to be dependent upon
EGF supplementation for anchorage-dependent clonal
growth. In mass culture, however, the cellular require-
ment for exogenous EGF by the 184 cells was consid-
erably attenuated, as shown in Fig. 1A. The 184A1N4
cells were more sensitive to EGF deprivation both in
mass cell culture and under clonal growth conditions.
All oncogene transformed cells were tested for an-
chorage-dependent growth responses to EGF in their
regular medium containing 10% fetal bovine serum
(FBS). Parallel experiments performed in the low serum
variant medium normally used for the 184A1N4 cells
without EGF supplementation and containing 0.5% FBS
as well as hydrocortisone and insulin showed no effect
of serum content on the cellular responsiveness to EGF
(data not shown). Figure 1B shows the results of "tests
in the regular growth medium for the cells, in the
presence of 10% FBS for the oncogene transformants
and 0.5% FBS for the 184A1N4 cells. Of the oncogene
transformants, only the 184A1N4-T and 184A1N4-M
cells could be additionally stimulated by EGF. When
assayed for anchorage-independent growth (Fig. 2), the
different cell lines displayed large variations in basal
and EGF/TGFa-induced cloning. 184 and 184A1N4
cells did not clone under anchorage-independent con-
ditions. 184A1N4-T did not clone in the absence of
EGF. In the presence of 5 ng/ml EGF or TGFa, how-
ever, 184A1N4-T displayed colony forming efficiencies
of up to 7% comparable to the cloning efficiencies of
the established breast cancer cell lines MCF-7 and
MDA-MB 231 (not shown). EGF or TGFa did not facili-
tate anchorage-independent cloning in the other onco-
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Fig. 1. HMEC Anchorage-Dependent Growth Response to EGF
A, EGF requirement of 184 and 184A1N4 cells at clonal density vs. mass culture. 184 and 184A1N4 (abbreviated A1N4 in figure)
were tested for dependence upon EGF supplementation in MCDB 170 medium. Clonal density: 500 cells were seeded into 100-
mm dishes. After 10-13 days, colonies greater than or equal to 30 cells were counted. Mass culture: 5 x 1 0 " cells were seeded
into 35-mm dishes. All cells were counted when control dishes were just confluent. D, No EGF. M, 5 ng/ml EGF. NG, No growth.
Growth reduction in the absence of EGF was significant in all tests (P < 0.01) except for mass culture of 184 (not significant). B,
Anchorage-dependent growth response of oncogene transformed HMEC to EGF. The immortalized and oncogene transformed
HMEC were tested for anchorage-dependent growth response to EGF in their respective regular growth media containing 0.5%
FBS for the 184A1N4 cells and 10% FBS for the oncogene transformants. Cells (0.5 or 1 x 104) were seeded in 12-well cluster
dishes. After allowing cell attachment, medium was changed to ±5 ng/ml EGF. After 5 days incubation, cells were trypsinized and
counted. *, P < 0.05; **, P < 0.01.
gene transformants. Their basal cloning efficiencies
were 0.6% for both 184A1N4-M and 184A1N4-H, 2.3%
for 184A1N4-MH, and 27.5% for 184A1N4-TH.
Expression of TGFa mRNA by HMEC
To ascertain whether normal HMEC express TGFa
mRNA and if the level of expression increases after
oncogenic transformation of these cells, total cellular
mRNA was subjected to Northern blot hybridization
using a synthetic TGFa riboprobe. RNA extracted from
four established human breast cancer cell lines were
included for comparison. As shown in Fig. 3, the phe-
notypically normal 184 and 172 cells and all the trans-
formed 184A1N4 sublines displayed similar, high levels
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Fig. 2. Anchorage-Independent Growth Response of HMEC to EGF
Two x 104 cells were plated in their respective regular growth medium with 0.36% Bacto agar in 35-mm dishes, with or without
5 ng/ml EGF. 184 and 184A1N4 were tested only in the presence of EGF. After 9-11 days, colonies greater than or equal to 60
^m were counted. Cloning efficiencies shown are means ± SD of triplicates of three separate experiments. D, No EGF. M, 5 ng/
ml EGF.
of a 4.8 kilobase (kb) TGFa mRNA (3). Gels were
comparably loaded as seen in ethidium bromide stain-
ing. The TGFa signal was found by densitometric scan-
ning to vary no more than 1.8-fold among the HMEC,
and less than 2.4-fold when normalized to the 28S
ribosomal RNA. A less abundant 1.6 kb mRNA species
was also observed on some of the blots. This species
has been previously reported in several human breast
cancer cell lines (10); however, its significance remains
unknown. Levels of these TGFa mRNA transcripts for
all the HMEC were comparable to levels in the aggres-
sive human breast cancer cell lines MDA MB-231 and
MDA MB-468.
Production of TGFa in Conditioned Medium (CM)
In agreement with the Northern blot analysis for TGFa
mRNA expression, all the oncogene transformed HMEC
produced comparable levels of TGFa, with no signifi-
cant differences in immunoreactive and bioactive pro-
tein production observed between the different cell lines
(Table 2). Although the 184 cells displayed the same
levels of TGFa mRNA, they produced higher amounts
of TGFa immunoreactive protein than the oncogene
transformants. 184 HMEC require a complex serum-
free medium containing EGF, bovine pituitary extract,
and insulin for their growth (20, 22). Deletion of the
EGF, bovine pituitary extract, and insulin from the me-
dium resulted in a 5-fold reduction in the CM levels of
TGFa from the 184 cells to a level which was com-
parable to the levels in the 184A1N4 cells and the
transformed 184A1N4 sublines. The apparently slightly
higher levels of bioactive than immunoreactive TGFa in
the 184 cells are probably due to trace amounts of
EGF-containing medium having been left behind despite
the washes before the CM collections, and are consid-
ered to be within the limits of our assay systems.
Expression of EGF-R mRNA and EGF-R Binding
Characteristics
Since variations in TGFa production could not explain
the observed phenotypic differences, and since varia-
tions in a possible autocrine loop may occur at the level
of the receptor for this growth factor, EGF-R expression
was examined in the various HMEC lines. Using an
EGF-R nick-translated cDNA insert from pE7, Northern
blots of total RNA from the 184 transformed series,
172, and two breast cancer cell lines were probed for
expression of EGF-R mRNA. As shown in Fig. 4A, high
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levels of specific hybridization to the 10 kb EGF-R
mRNA species and in some cases the 5.6 kb species
(23), were found in all the HMEC lines. By densitometric
scanning the EGF-R signal was found to vary less than
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Fig. 3. Expression of TGFa mRNA in Proliferating Normal and
Transformed HMEC
Northern blot analysis of 8 ng total RNA hybridized to the
TGFa riboprobe is shown. RNA samples from human breast
cancer cell lines MDA MB 231 and MDA 468 are included as
positive controls (lanes 1 and 3), Hs578T as a negative control
(lane 2), and MCF-7 as a weakly positive control (lane 4).
Ethidium bromide stain of the gel (lower panel) showed that
samples were undegraded and comparably loaded.
2.0-fold among the HMEC, and less than 2.5-fold when
normalized to the /8-actin signal. The high levels of
expression observed in the HMEC lines contrast
sharply with the EGF-R mRNA expression in MCF-7
cells which in our hands is not detectable in Northern
analysis of total RNA.
Southern blots of DNA digestion with H/ndlll were
probed with the same labeled pE7 probe and showed
no apparent EGF-R gene overexpression or re-
arrangements in the HMEC (Fig. 4B). A breast cancer
cell line with known EGF-R amplification, MDA MB-468
(24), is shown for comparison. Densitometric scanning
showed a maximum of 1.7-fold difference in band inten-
sities among the HMEC.
In several other systems, either mos or ras transfor-
mation has been shown to cause loss of detectable
EGF-R binding, probably due to a down regulation
induced by an increase in TGFa production (16, 25,
26). EGF-R binding characteristics were therefore de-
termined for all the 184 cell lines. In order to measure
only cell surface receptor binding and to avoid obscur-
ing determinations of 125I-EGF binding characteristics
due to possible receptor internalization and degradation
of 125I-EGF-R complexes, all ligand binding assays were
performed at 4 C. As shown in Table 3,184,184A1N4,
and 184A1N4-M all had approximately 3-4 x 105 total
binding sites per cell. The 184A1N4, 184A1N4-M, and
184A1N4-T cell lines clearly demonstrated both high
and low affinity binding sites (Fig. 5). (P values for two-
site model fits were 0.034, 0.014, and 0.001 for
184A1N4,184A1N4-M, and 184A1N4-T, respectively).
The 184A1N4-T cells exhibited markedly elevated levels
Table 2. Detection of TGFa-Like Activity in CM
Cell RIA(ng/ml CM) (pg/Mg DNA)
NRK-49F
(ng/ml CM) (pg/Mg DNA)
184
(complete medium)
184
(-EGF, BPE, insulin)
A1N4
A1N4-M
A1N4-T
A1N4-H
A1N4-MH
A1N4-TH
Established breast cancer lines: (RIA)
MCF-7
MCF-7 + E2
MDA-MB-231
1.04 ±0.26
0.19 ±0.05
0.14 ±0.01
0.11 ±0.04
0.17 ±0.12
0.10 ±0.03
0.14 ±0.01
0.18 ±0.08
1.3 ± 0.5 pg/(
10.0 ±1.4
10.2 ±0.8
184 ±46
41 ± 6
45 ± 2
11 ±4
21 ±17
9 ± 3
17±2
22 ±10
ug DNA
ND
0.60 ± 0.06
ND
0.16 ±0.02
0.14 ±0.06
0.29 ± 0.09
0.24 ± 0.01
0.20 ± 0.03
ND
159 ±58
ND
10±4
21 ±7
29 ±3
31 ±6
28 ±9
ND, Not determined. Concentrated CM from the normal and transformed HMEC lines were assayed for TGFa-like activity using the
TGFa RIA kit (Biotope, Inc.) and induction of NRK 49F fibroblast cloning in soft agar. For the RIA, results shown are means ± SD
of duplicate determinations from three separate experiments on two different CM collections. Values represent the TGFa activity
remaining in CM after subtraction of media blanks. For 184 cells, medium blank was 26% (0.38 ± 0.18 ng/ml) of total TGFa levels
in complete medium (which were 1.47 ± 0.19 ng/ml). For 184A1N4 cells, medium blank was 0.02 ng/ml, i.e. 11% of total TGFa
levels (which were 0.16 ± 0.01 ng/ml). All medium blank values have been subtracted before calculations of averages and standard
deviations shown in the table. Media blanks for the oncogene-transformants showed no immunoreactivity or biological activity.
Values for breast cancer cell lines MCF-7 and MDA MB 231 are shown for comparison. For quantification in the NRK assay, three
dilutions of CM were assayed in triplicates in two separate assays, using two separate CM collections. Calculations were normalized
to mouse EGF titrations.
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Fig. 4. EGF Receptor Gene Expression in HMEC
A, Expression of EGF receptor mRNA in proliferating normal
and transformed HMEC. Northern analysis of 8 ng total RNA
hybridized to the nick-translated cDNA insert from pE7, en-
coding the EGF-R. RNA samples from cell lines Hs578T and
MCF-7 are included as controls. These lines have been shown
to contain 9.0 x 10" and 2.4 x 103 binding sites per cell,
respectively (53). Ethidium bromide staining showed that all
samples contained comparable amounts of RNA. The lower
panel shows hybridization of the /8-actin probe to a 2.1 kb
mRNA species. B, Analysis of the EGF receptor gene in HMEC.
Southern analysis of 5 ng DNA was performed after digestion
of the DNA with H/ndlll and hybridization with the nick-trans-
lated pE7 EGF-R encoding insert. The slight variations in band
intensities among the oncogene transformed HMEC corre-
spond to amounts loaded as seen in ethidium stain of the gel
(not shown). The breast cancer cell lines MDA MB 231, MDA
MB 468, and MCF-7 are included for comparison. The MDA
MB 468 breast cancer cell line has been shown to have an
amplified EGF-R gene (24).
of both EGF binding components. This was reproduci-
ble using cells either at early passage level or cells that
had been propagated for 6-7 months, ruling out the
potential possibility that a gradual selection had oc-
curred during long-term serial passage of these cells. It
is noteworthy that while the 184A1N4-T cells showed
5- to 10-fold greater number of EGF binding sites
compared to the other cells studied, this difference was
not mirrored at the mRNA level.
Although the total number of binding sites in the three
cell lines containing v-Ha-ras were only slightly lower
than in 184A1N4 cells, two-site computer fitted models
gave less than 100 binding sites per cell for the high
affinity component (Fig. 5).
DISCUSSION
Expression of TGFa by HMEC: Lack of Induction
after Malignant Transformation
This study was undertaken to examine the expression
of TGFa and the EGF/TGFa receptor in normal, prolif-
erating, nonimmortal, reduction mammoplasty-derived
HMEC and in sublines of the normal mammary epithelial
cells that had been immortalized with benzo-a-pyrene
and subsequently transformed to various degrees by
single or combinations of viral oncogenes. The cells
displayed marked variations in response to exogenous
EGF or TGFa, ranging from an almost complete de-
pendence upon supplementation for survival to auton-
omous growth and complete insensitivity. The SV40 T
transformed cells required EGF or TGFa for anchorage-
independent cloning. All lines carrying a v-Ha-ras on-
cogene had lost responsiveness to exogenous EGF or
TGFa under anchorage-dependent and independent-
growth conditions. Also, v-Ha-ras abrogated the SV40
T induced hypersensitivity to EGF or TGFa in soft agar
and was synergistic with SV40 T in facilitating anchor-
age-independent cloning.
Biologically active and immunoreactive TGFa and its
mRNA were produced by both the normal and malig-
nant HMEC. Furthermore, no additional increase in
TGFa expression was observed as the 184A1N4 cells
progressed to an increasingly malignant phenotype
after oncogene transformation. Rather, the normal pa-
rental 184 cells apparently produced more TGFa im-
munoreactive protein than the 184A1N4 cells or the
transformed sublines. The mechanism(s) responsible
for the decreased TGFa protein/mRNA ratio in the
transformed HMEC 184A1N4 lines is not yet under-
stood, and may involve altered posttranslational proc-
essing. The slightly higher levels of bioactive than im-
munoreactive TGFa in the 184 cells is not considered
significant, since the bioassay would not discriminate
between TGFa produced by the cells and traces of
exogenous EGF left behind despite the washes preced-
ing the CM collections.
Taken together, these results imply that in breast
cancer, TGFa may not be a tumor specific growth
factor. This is supported by several other reports dem-
onstrating the presence of TGFa (27-29) or TGFa-like
activity (30-32) in a number of other normal cells and
tissues, including human milk.
The observation that TGFa production was not in-
creased with oncogene mediated progression of HMEC
to a more malignant phenotype contrasts to previous
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Table 3. Binding Parameters for the EGF-Receptor on HMEC
Cell KD (high)(nM)
KD (low)
(nM)
Bmax (high)
Sites/Cell
(x103)
Bm ax (lOW)
Sites/Cell
(X103)
Bmax (tot)
Sites/Cell
(X103)
184
A1N4
A1N4-M
A1N4-T
A1N4-H
A1N4-MH
A1N4-TH
0.19 ±0.05
0.14 ±0.14
0.16 ±0.07
0.10 ±0.03
1.12 ±0.39
2.24 ± 0.43
1.75 ±0.13
3.21 ± 0.45
0.57 ± 0.22
2.04 ± 0.27
403 ± 234
21 ± 10
28 ± 11
72 ± 6
290 ± 1 5
353 ± 90
1979 ± 177
278 ± 33
163 ± 4 7
184 ± 1 9
403 ± 24
308 ± 1 7
381 ± 97
2051 ±183
278 ± 33
163 ± 4 7
184 ± 1 9
All values are expressed as means ± SEM. Binding parameters for the EGF-R were computed from whole cell monolayer saturation
experiments, as described in Materials and Methods. Two-site computer model fits could not be calculated for 184A1N4-H, and
gave less than 100 binding sites per cell for 184A1N4-MH and 184A1N4-TH.
reports. For example, in both mouse mammary epithe-
lial cells and rodent fibroblasts, various oncogenes in-
duced increased expression of TGFa (1, 16, 33, 34)
and transformation and desensitization to exogenous
EGF were proposed to directly result from overexpres-
sion of endogenous TGFa. It should be noted that in
the rodent cell lines, ras alone was sufficient to elicit full
transformation, which was not the case with the HMEC
used in the present study. For the HMEC, cooperation
between SV40 T and v-Ha-ras (but not v-mos and v-
Ha-ras) in previously immortalized cells was required
for expression of the fully malignant phenotype.
Expression of EGF-R by HMEC: v-Ha-ras
Suppression of High Affinity Sites and SV40 T
Induced Receptor Expression
To determine whether transformation and variations in
growth factor responses of the HMEC lines were due
to alterations at the level of EGF-R expression rather
than to changes in TGFa production, EGF-R binding
characteristics and mRNA expression were determined
in all the HMEC lines. EGF-R was expressed at high
levels in all the HMEC lines, with less than a 2-fold
reduction in total number of binding sites per cell in the
184A1N4 cell lines transformed by two oncogenes.
However, the presence of v-Ha-ras oncogene in any of
the cell lines was associated with a loss of the high
affinity EGF-R binding component. These findings are
in agreement with several other studies demonstrating
a reduction in high affinity EGF-R binding in the pres-
ence of a v-Ha-ras oncogene or activated c-Ha-ras
proto-oncogene (16, 35) or other viral oncogenes such
as mos or abl (34, 36, 37).
The 184A1N4 cell line transformed by SV40 T alone
was found to express 5- to 10-fold more EGF-R binding
sites than all the other HMEC lines, without a corre-
sponding increase in EGF-R mRNA levels. The mech-
anism for this is not clear but may involve regulation at
a posttranscriptional level. In these cells, TGFa or EGF
induced cloning in soft agar, whereas the other onco-
gene transformants were unresponsive to EGF/TGFa
under anchorage-independent growth conditions. Our
observations of the necessary interaction between a
high number of EGF-R and presence of an appropriate
ligand for eliciting the fully transformed phenotype in
the HMEC transformed by SV40 T, are paralleled in
two recent studies using the mouse fibroblast NIH 3T3
cells transfected with a functional EGF-R (38, 39). In
both studies, the cells displayed soft agar growth and
focus formation only in the presence of exogenous
EGF. It is noteworthy that cells of such divergent origins
as human epithelial cells and rodent mesenchymal cells
should possess such similar characteristics. This may
indicate the existence of a still unknown common path-
way to transformation. In contrast, two other human
epithelial cell lines with constitutive overexpression of
even higher levels of EGF-R, the epidermoid carcinoma
line A431 (40) and the MDA MB-468 breast cancer cell
line (24), are both growth inhibited by EGF. On the other
hand, enhanced responsiveness to EGF can be induced
in rodent and chicken mesenchymal cells overexpress-
ing c-src or c-myc, respectively (41-43), without alter-
ations in cellular phenotype or EGF-R expression. All of
these studies, including our present findings, indicate
that elevated levels of EGF-R may be necessary in
some cases but are not sufficient in all cases for eliciting
the malignant phenotype, and that additional activation
at some other level may be required.
The Autocrine Hypothesis in Relation to Oncogene
Induced Transformation of HMEC
An autocrine feedback loop involving TGFa may be
functioning for the nontransformed HMEC. In mass
culture, they have reduced requirement for exogenous
EGF and produce substantial amounts of TGFa activity,
apparently enough to partially abrogate their require-
ments for exogenous EGF. It may be that the TGFa/
EGF-R system is related to a common mechanism of
cellular growth control in both normal and malignant
breast epithelial cells and that overrexpression of either
TGFa and/or the EGF-R may not be unique to tumor
cells. In this respect, it has recently been shown in
human keratinocytes by in situ hybridization with a
TGFa riboprobe (5) that the highest levels of TGFa
expression were observed in the basal cell layer, a
putative stem cell population with the highest prolifer-
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Fig. 5. Scatchard Plots for 125I-EGF Binding to the HMEC Lines
Saturation binding curves of 125I-EGF for EGF-R on whole cell monolayers were performed using 1 pM-25 nM 125I-EGF at 4 C,
with the addition of greater than or equal to 100-fold excess unlabeled EGF for nonspecific binding. Binding parameters were
computed using the LIGAND program.
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ation rates in the epidermis. Furthermore, whereas
primary chemically-induced rat mammary tumors pro-
duce TGFa, transplantable rat mammary tumors, which
were derived from these same tumors, express little or
no TGFa (44). It is possible that differential responses
to EGF/TGFa, rather than changes in the levels of
production of endogenous TGFa, are associated with
the transition from normal to malignant breast epithe-
lium.
Taken together, these observations suggest that on-
cogenes may alter normal cellular growth in a neoplastic
direction without obvious effects on TGFa production
and/or EGF-receptor expression and function. As illus-
trated by the SV40 T transformed line, the presence of
an oncogene can considerably increase the number of
EGF-R binding sites without conferring an obviously
transformed phenotype. In the presence of exogenous
ligand, however, transformation is induced as measured
by anchorage-independent growth. In contrast, ras is
capable of inducing transformation in the absence of
obvious changes in either TGFa production or EGF-R
binding characteristics, and abrogates cellular respon-
siveness to exogenous EGF/TGFa. In this system,
SV40 T and ras appear to have synergistic effects in
eliciting the fully transformed and malignant phenotype.
Evidently, this occurs via a mechanism other than direct
alterations in the TGFa/EGF-R system. Perhaps a sus-
tained activation of the intracellular EGF-R transduction
process is caused by the G-protein-like properties of
the p21 ras protein (35), thus bypassing activation of
the EGF cell surface receptor. The SV40 T and v-Ha-
ras oncogenes may interact only coincidental^ with
TGFa production or EGF-R expression, while inducing
phenotypic transformation at another level. Clearly, on-
cogenes may have effects on growth factor pathways
in addition to simply augmenting growth factor produc-
tion, as initially proposed.
MATERIALS AND METHODS
Cell Lines
Normal HMEC strains 184 and 172 were routinely cultured in
serum-free MCDB 170 medium (University of California at San
Francisco, Tissue Culture Unit) containing EGF, bovine pitui-
tary extract, and insulin, as previously described (45), in a less
than or equal to 1.0% CO2 atmosphere. Experiments were
performed with cell cultures at passages 10-12. 184A1N4, a
subclone of the established immortalized benzo-a-pyrene
treated line 184A1 (20), was routinely grown in a variant
medium consisting of Improved Modified Eagle's Medium
(IMEM) (GIBCO, Grand Island, NY) with 0.5% FBS (GIBCO),
insulin (10 /ig/ml; Sigma, St. Louis, MO), hydrocortisone (0.1
/xg/ml; Sigma), and EGF (5 ng/ml; Collaborative Research,
Bedford, MA), in 5% CO2 atmosphere. The oncogene-trans-
formed (not clonally selected) lines 184A1N4-T, 184A1N4-M,
184A1N4-TH, and 184A1N4-MH (carrying SV40 T, v-mos, v-
Ha-ras, or SV40 T + v-Ha-ras, v-mos + v-Ha-ras, respectively)
(21) were maintained in IMEM supplemented with 10% FBS.
184 cells are normal diploid, 184A1N4 near triploid, 184A1N4-
T near hexaploid (Clark, R., unpublished data), and two clones
of 184A1N4-TH were near tetraploid.
MCF-7 cells were donated by Dr. Marvin Rich, Michigan
Cancer Foundation (Detroit, Ml). HT1080 fibrosarcoma cells,
MDA-MB-231, MDA-M8-468, and normal rat kidney cells
(NRK) clone 49F were obtained from the American Type
Culture Collection (Rockville, MD); Hs578T was provided by
Helene Smith, Peralta Cancer Research Institute (Oakland,
CA). All of these cell lines were maintained in IMEM with 10%
FBS, in 5% CO2 atmosphere.
Effect of EGF/TGFa on Anchorage-Dependent and
Anchorage-Independent Growth
Anchorage-dependent requirement for EGF by 184 and
184A1N4 cells was tested at clonal density and in mass
culture. For assays at clonal densities, freshly trypsinized cells
were seeded into 100-mm dishes, 500 cells per dish, in regular
MCDB 170 medium with or without 10 ng/ml EGF. After 10-
13 days incubation without refeeding, plates were stained and
colonies were counted. For assaying EGF dependence at high
cellular densities, 5 x 104 cells were seeded into 35-mm dishes
in MCDB 170 medium in the absence or presence of EGF (10
ng/ml). Medium was changed every 2-3 days during the
culture period, and when control dishes were just confluent,
the cells were trypsinized and counted. Results represent the
average of triplicate determinations from two experiments for
each growth condition tested.
Growth responses of the oncogene transformed cells were
evaluated on cells plated in 12-well cluster dishes, 5-10 x 103
cells per well, in IMEM containing 10% FBS. Medium was
changed and EGF or TGFa were added 4 h after plating. The
cells were trypsinized and counted after 5 days of culture while
still less than 90% confluent. Results represent the average of
triplicate determinations from three separate experiments.
Anchorage-independent growth responses to 5 ng/ml EGF
or TGFa were tested by plating 0.8 ml/35-mm dish of mixture
containing 2 x 1 0 " cells in their regular growth medium in the
presence or absence of EGF or TGFa and 0.36% (vol/vol)
Bactoagar. After 9-11 days incubation, colonies greater than
or equal to 60-mm diameter were counted on a Bausch &
Lomb stem cell colony counter. Results represent the average
of triplicate determinations from three separate experiments.
Preparation of CM
Cells were grown to 75-85% confluency in T-175 tissue
culture flasks (Falcon Oxnard, CA) in their regular growth
media. After an overnight serum-free medium wash, serum-
free medium was collected after 48 h of conditioning (at which
time the cells were generally less than or equal to 95%
confluent). The 184 parent cells were either maintained in the
MCDB 170 mixture routinely used for their growth or in MCDB
170 medium without bovine pituitary extract, EGF, and insulin,
in the presence of prostaglandin E2 (Sigma) (22). For the
184A1N4 cells, CM consisted of variant medium without FBS.
For the oncogene-transformed 184A1N4 lines and for control
cell lines, serum-free medium consisted of IMEM supple-
mented with transferrin (2 mg/liter; Sigma), fibronectin (1 mg/
liter; Collaborative Research), HEPES buffer (20 ITIM; GIBCO),
and trace elements (GIBCO). After collection of the CM, pro-
tease inhibitors aprotinin (0.2% vol/vol) (Sigma), leupeptin (2
jtg/liter) Boehringer-Mannheim, Indianapolis, IN), and phenyl-
methylsulfonylfluoride (10~7 M) (Sigma) were added, media
were filtered stored at -20 C. At the time of assay, CM was
thawed, and concentrated and dialyzed against distilled H2O
on Centriprep centrifugal devices (Amicon Danvers, MA) as
described in the manufacturer's instructions. Aliquots of 50-
fold concentrated medium were assayed at various dilutions
for TGFa-like activity as described below.
DNA was quantitated using a fluorescence method (46)
from aliquots of pooled cells harvested from the same flasks
from which CM had been collected.
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Detection of TGFa-Like Activity in CM
CM was assayed both for TGFa-immunoreactivity, using a
TGFa RIA kit (Biotope, Inc.), and for EGF/TGFa bioactivity by
induction of anchorage-independent colony growth of NRK
49F cells. Complete MCDB 170 medium CM from 184 cells,
and variant medium CM from 184A1N4 cells, which contained
EGF, could only be assayed by the RIA. Several dilutions of
concentrated and dialyzed CM from three separate collections
were assayed by both methods.
The presence in CM of biologically active TGFa activity on
NRK 49F cells in soft agar was assayed as previously de-
scribed (4) using 3.2-12.5 ml equivalents of CM plated with 3
x 103 cells in the presence of 2.6 ng/ml TGF/3 (34) in 0.36%
Bacto-agar in 35-mm dishes. Different concentrations of
mouse EGF were used as a reference for calibrating the
amount of TGFa in the CM aliquots as determined from
standard titration curves using mouse EGF and human TGFa.
EGF and TGFa are equipotent in this bioassay (10, 16, and
data not shown). Plates were counted after 7 days using a
Bausch & Lomb stem cell colony counter. Colonies of greater
than or equal to 60 nm diameter were scored as positive. Two
separate experiments with triplicates of every dilution of CM
were performed.
TGFa immunoreactivity was assayed in CM using a TGFa
RIA kit (Biotope, Inc., Seattle, WA) with a polyclonal anti-rat
TGFa antibody which recognizes reduced and denatured hu-
man and rat TGFa, but does not cross-react with up to 1 HM
mouse EGF (47 and data not shown). Standard curves of
unlabeled rat TGFa, against which the antibody was raised,
were performed in competition with trace amounts of 125l-rat
TGFa. The limit of detection of the RIA for TGFa was approx-
imately 0.08 ng/assay with 50% displacement of labeled pep-
tide occurring at approximately 0.7 ng/assay. Duplicate or
triplicate tests were performed in three separate experiments
on dilutions of each individual CM sample.
EGF Receptor Binding
Whole-cell EGF-receptor analyses were performed as de-
scribed (48). Briefly, oncogene transformed cells were grown
to confluency in poly-D-lysine coated 24-well cluster dishes
(Falcon) in IMEM with 5% FBS and washed and incubated
with serum-free medium (composed as described for CM) for
3-7 h before the binding assay in order to reduce nonspecific
competition by serum factors. The 184 and 184A1N4 cells
were incubated overnight in their regular medium without
bovine pituitary extract, EGF, or FBS, before EGF receptor
analysis. Binding was carried out in Hank's Basic Salt Solution
(with 0.1% BSA and 40 miwi HEPES, pH 7.4) containing either
varying concentrations of 125I-EGF (human, ICN Radiochemi-
cal, Irvine, CA; SA, 80-160 MCi//xg), or varying concentrations
of unlabeled mouse EGF with a constant amount of labeled
EGF. Nonspecific binding was assayed in the presence of
greater than or equal to 100-fold excess unlabeled mouse
EGF. After incubation for 2.5 h at 4 C, cells were washed with
ice-cold binding buffer on ice and solubilized in lysis buffer
(0.01 M Tris-HCI, pH 7.4, 1 ITIM EDTA, 0.5% sodium dodecyl
sulfate SDS). Lysates were counted in an LKB 7-counter.
Three to six separate experiments were performed on each
cell line, and binding sites were normalized to cell numbers
determined from parallel wells which had been comparably
treated. Preliminary kinetic binding experiments showed that
equilibrium was attained for the high affinity binding component
and approximated for the low affinity component (data not
shown).
RNA Preparation and Northern Blot Analysis
Total cellular RNA was isolated by centrifugation of guanidine
isothiocyanate homogenates over cushions of cesium chloride,
and total RNA was electrophoretically separated on 1 % aga-
rose-6% formaldehyde gels as previously described (10). Gels
were examined after staining with 2 Mg/ml ethidium bromide
to ensure that only comparably loaded and undegraded RNA
samples were used. Subsequently, gels were subjected to
alkaline hydrolysis, neutralization, and Northern transfer to
nitrocellulose by capillary blot. The Northern blots were hybrid-
ized to TGFa or EGF-R synthetic riboprobes. A synthetic TGFa
riboprobe was prepared by SP6 polymerase transcription of a
1.3 kb TGFa cDNA insert (49) ligated into plasmid SP65,
received from Rik Derynck (Genentech, Inc., South San Fran-
cisco, CA). An EGF-R riboprobe was synthesized from a 136
basepair sequence isolated from pE7 (gift of Glen Merlino,
NCI) (23) and cloned into pGEM4. Finally, a 1.7 kb /3-actin
cDNA (50) cloned into pGEM3 was used to construct a /3-actin
riboprobe with SP6 polymerase.
Nitrocellulose filters were hybridized in 50% formamide, 5x
Denhardt's, 5x SSC, 0.1 % SDS, and 200 Mg/ml salmon sperm
DNA for 18 h at 55 C for the riboprobes (2 x 106 cpm/ml).
Filters probed with riboprobes were washed twice for 30 min
at 21 C in 1 x SSC + 0.1% SDS warmed to 68 C; and in 0.1 x
SSC + 0.1% SDS for 1 h in a 68 C water bath. Filters probed
with nick-translated cDNAs were washed at 21 C in 2x SSC
+ 0.2% SDS for 1 h, followed by 1x SSC + 0.1% SDS
warmed to 42 C. Autoradiography was performed with Kodak
XAR-5 film at -70 C. Autoradiograms were subsequently
quantified by densitometric scanning in a Beckman gel scan-
ner.
DNA Preparation and Southern Blot Analysis
High molecular weight DNA was isolated by SDS-proteinase
K lysis, RNAse A digestion, extraction with phenol and chlo-
roform, and precipitation with sodium acetate in cold ethanol.
DNA was digested with H/ndlll, electrophoresed in an 0.8%
agarose gel, and transferred to nitrocellulose filters by South-
ern blotting. Nitrocellulose filters were baked in a vacuum oven
for 2 h at 80 C. Hybridizations were performed with 1 x 106
cpm/ml nick-translated cDNA insert pE7 (23). Molecular size
markers used were H/ndlll fragments of lambda DNA (Be-
thesda Research Laboratories, Gaithersburg, MD).
Data Analyses
Receptor binding parameters for saturation and displacement
experiments were calculated using the LIGAND computer
program (51). Nonspecific binding was estimated together with
the other binding parameters and did not exceed 3% in any
assay (51).
All parameters obtained are expressed as means ± so (for
mitogenic assays) or means ± SEM (for receptor binding as-
says). Means were compared using the two-tailed Student's t
test (52). Values of P < 0.05 were taken to indicate statistical
significance.
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